title: Cytochrome P450 2D6 as a model antigen.
abstract: Cytochrome P450 2D6 (CYP2D6) has been identified as the major autoantigen in type 2 autoimmune hepatitis (AIH). However, because of a lack of appropriate animal models, the etiology of AIH is still poorly understood. We generated a mouse model for AIH using the human CYP2D6 as a triggering molecule for autoimmunity. We infected wild-type FVB mice with an adenovirus expressing human CYP2D6 (Ad-2D6) to break self-tolerance to the mouse CYP2D6 homologues. Ad-2D6-infected mice showed persistent features of liver damage including hepatic fibrosis, cellular infiltrations, focal-to-confluent necrosis and generation of anti-CYP2D6 antibodies, which predominantly recognized the identical immunodominant epitope recognized by LKM-1 antibodies from AIH patients. Interestingly, Ad-2D6 infection of transgenic mice expressing the human CYP2D6 (CYP2D6 mice) resulted in delayed kinetics and reduced severity of liver damage. However, the quantity and quality of anti-CYP2D6 antibodies was only moderately reduced in CYP2D6 mice. In contrast, the frequency of CYP2D6-specific CD4 and CD8 T cells was dramatically decreased in CYP2D6 mice, indicating the presence of a strong T cell tolerance to human CYP2D6 established in CYP2D6 mice, but not in wild-type mice. CYP2D6-specific T cells reacted to human CYP2D6 peptides with intermediate homology to the mouse homologues, but not to those with high homology, indicating that molecular mimicry rather than molecular identity breaks tolerance and subsequently causes severe persistent autoimmune liver damage. The CYP2D6 model provides a platform to investigate mechanisms involved in the immunopathogenesis of autoimmune-mediated chronic hepatic injury and evaluate possible ways of therapeutic interference.
authors.affiliation: Klinikum der Goethe-Universität Frankfurt am Main, Pharmazentrum/ZAFES, Frankfurt am Main, Germany. christen@med.uni-frankfurt.de
authors.forename: Urs
authors.initials: U
authors.lastname: Christen
authors.forename: Martin
authors.initials: M
authors.lastname: Holdener
authors.forename: Edith
authors.initials: E
authors.lastname: Hintermann
mesh_terms: D000256:Adenoviridae; D000818:Animals; D000917:Antibody Formation; D000941:Antigens / Q000276:immunology*; D001324:Autoantigens / Q000276:immunology; D015496:CD4-Positive T-Lymphocytes / Q000276:immunology; D018414:CD8-Positive T-Lymphocytes / Q000276:immunology; D019389:Cytochrome P-450 CYP2D6 / Q000276:immunology*; D004195:Disease Models, Animal; D005822:Genetic Vectors; D019693:Hepatitis, Autoimmune / Q000276:immunology* / Q000473:pathology; D006801:Humans; D007108:Immune Tolerance; D008099:Liver / Q000473:pathology; D051379:Mice; D008822:Mice, Transgenic; D018716:Molecular Mimicry
chemical_list: D000941:Antigens; D001324:Autoantigens; D019389:Cytochrome P-450 CYP2D6
references.citation: Nat Med. 2003 Jul;9(7):914-20
references.pmid: 12819778
references.citation: J Autoimmun. 1991 Aug;4(4):607-15
references.pmid: 1723273
references.citation: J Exp Med. 2008 Jun 9;205(6):1409-22
references.pmid: 18474629
references.citation: Clin Exp Immunol. 1999 Nov;118(2):290-7
references.pmid: 10540193
references.citation: J Immunol. 2003 Feb 1;170(3):1481-9
references.pmid: 12538711
references.citation: Nat Rev Immunol. 2009 Apr;9(4):246-58
references.pmid: 19319143
references.citation: Semin Liver Dis. 2009 Aug;29(3):262-72
references.pmid: 19675999
references.citation: Cell. 1991 Apr 19;65(2):319-31
references.pmid: 1901765
references.citation: Eur J Immunol. 1993 May;23(5):1105-11
references.pmid: 7682958
references.citation: J Immunol. 2005 May 1;174(9):5874-83
references.pmid: 15845458
references.citation: Hepatology. 2008 Aug;48(2):531-40
references.pmid: 18563844
references.citation: J Autoimmun. 2001 Nov;17(3):243-9
references.pmid: 11712862
references.citation: Hepatology. 2006 Feb;43(2 Suppl 1):S132-44
references.pmid: 16447290
references.citation: Hepatology. 2003 Nov;38(5):1250-7
references.pmid: 14578864
references.citation: Biol Pharm Bull. 2005 Dec;28(12):2240-3
references.pmid: 16327157
references.citation: J Autoimmun. 2010 Feb;34(1):38-44
references.pmid: 19716269
references.citation: Mol Immunol. 2004 Feb;40(14-15):1113-20
references.pmid: 15036917
references.citation: Autoimmunity. 2002 Dec;35(8):501-13
references.pmid: 12765476
references.citation: Proc Natl Acad Sci U S A. 1988 Nov;85(21):8256-60
references.pmid: 3186722
references.citation: J Clin Invest. 1991 Oct;88(4):1370-8
references.pmid: 1717511
references.citation: FASEB J. 1998 Oct;12(13):1255-65
references.pmid: 9761770
references.citation: Hepatology. 2007 Aug;46(2):472-84
references.pmid: 17559153
references.citation: Arch Biochem Biophys. 2000 Sep 15;381(2):191-204
references.pmid: 11032406
references.citation: Immunity. 1994 Jun;1(3):231-42
references.pmid: 7889411
references.citation: J Clin Invest. 1989 Mar;83(3):1066-72
references.pmid: 2466049
references.citation: Curr Opin Immunol. 2004 Dec;16(6):759-67
references.pmid: 15511670
references.citation: Nat Immunol. 2002 Jul;3(7):627-34
references.pmid: 12055626
references.citation: Gastroenterology. 2006 Mar;130(3):868-82
references.pmid: 16530525
references.citation: J Immunol. 1992 Aug 1;149(3):789-95
references.pmid: 1321851
references.citation: Trends Immunol. 2004 Feb;25(2):61-6
references.pmid: 15102364
references.citation: Cell. 1991 Apr 19;65(2):305-17
references.pmid: 1901764
references.citation: Drug Metab Dispos. 2008 Jul;36(7):1322-31
references.pmid: 18420780
references.citation: Hepatology. 1996 Dec;24(6):1416-21
references.pmid: 8938173
references.citation: Drug Metab Dispos. 2006 Jul;34(7):1167-74
references.pmid: 16595712
references.citation: J Clin Invest. 2004 Nov;114(9):1290-8
references.pmid: 15520861